目的 探討沙巴棕軟膠囊聯(lián)合特拉唑嗪治療良性前列腺增生的臨床療效。方法 選取2017年2月-2017年6月鄭州市第一人民醫(yī)院收治的良性前列腺增生患者88例，隨機分為對照組（44例）和治療組（44例）。對照組睡前口服鹽酸特拉唑嗪片，2 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服沙巴棕軟膠囊，160 mg/次，2次/d。兩組患者均經(jīng)過3月治療。觀察兩組患者臨床療效，比較治療前后兩組患者前列腺體積、殘余尿量、最大尿流率（Q_max）、血清指標和國際前列腺癥狀（IPSS）評分。結(jié)果 治療后，對照組臨床有效率為79.55%，顯著低于治療組的95.45%。兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組前列腺體積、殘余尿量均顯著減小，而Q_max明顯增加，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組上述指標明顯好于對照組（P<0.05）。治療后，兩組血清Bcl-2、白細胞介素-6（IL-6）、IL-17水平均明顯降低，IL-2水平均明顯增加，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組上述指標明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者IPSS評分均明顯降低（P<0.05）；且治療組比對照組降低的更顯著（P<0.05）。結(jié)論 沙巴棕軟膠囊聯(lián)合鹽酸特拉唑嗪片治療良性前列腺增生可有效改善患者臨床癥狀和細胞因子水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Sabale Soft Capsules combined with terazosin in treatment of benign prostatic hyperplasia. Methods Patients (88 cases) with benign prostatic hyperplasia in the Medical Group of Zhengzhou First People's Hospital from February 2017 to June 2017 were randomly divided into control (44 cases) and treatment (44 cases) groups. Patients in the control group were po administered with Terazosin Hydrochloride Tablets, 2 mg/time, once daily. Patients in the treatment group were po administered with Sabale Soft Capsules on the basis of the control group, 160 mg/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the prostatic volume, residual urine volume, Q_max, the serological indexes and IPSS scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.55%, which was significantly lower than 95.45% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the prostatic volume and residual urine volume in two groups were significantly reduced, but Q_max was significantly increased, and there were differences in the same group (P < 0.05). And these indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the Bcl-2, IL-6 and IL-17 levels in two groups were significantly decreased, but IL-2 was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the serological indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the IPSS score in two groups were significantly decreased (P < 0.05), and the score in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Sabale Soft Capsules combined with terazosin in treatment of benign prostatic hyperplasia can effectively improve the clinical symptoms and the cytokines level, which has a certain clinical application value.